Comparative Pharmacology
Head-to-head clinical analysis: GONAL F RFF versus GONAL F RFF REDI JECT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GONAL F RFF versus GONAL F RFF REDI JECT.
GONAL-F RFF vs GONAL-F RFF REDI-JECT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular growth and maturation and spermatogenesis.
GONAL-F (follitropin alfa) is a recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian follicles, stimulating follicular growth, maturation, and estrogen production.
Subcutaneous injection, initially 75-150 IU once daily for 5-7 days for ovulation induction. For controlled ovarian hyperstimulation, 75-300 IU once daily starting day 2 or 3 of cycle. Dose adjusted based on response.
Subcutaneous injection. Initial dose 75-225 IU once daily for 7-14 days, titrated based on ovarian response. Maximum daily dose 450 IU.
None Documented
None Documented
Terminal elimination half-life: approximately 24-30 hours (range 24-36 h) following subcutaneous administration; supports once-daily dosing regimen.
Terminal elimination half-life: approximately 24 hours; clinically, steady-state is achieved within 3-5 days of daily dosing.
Renal excretion: approximately 70% of the dose is eliminated in urine as intact hormone and metabolites; fecal excretion is negligible (<5%).
Renal: approximately 70-80% of the dose; fecal: <20%
Category C
Category C
Gonadotropin
Gonadotropin